{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:09:43Z","timestamp":1740136183920,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13054-019-2639-7","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T10:03:11Z","timestamp":1573639391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Attainment of therapeutic vancomycin level within the first 24\u2009h: Authors' response"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-806X","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Baptista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Devesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"issue":"4","key":"2639_CR1","first-page":"48","volume":"13","author":"HM Al-Dorzi","year":"2019","unstructured":"Al-Dorzi HM, Eissa AT, Khan RM, Harbi SAA, Aldabbagh T, Arabi YM. Dosing errors of empirical antibiotics in critically ill patients with severe sepsis or septic shock: a prospective observational study. Int J Health Sci (Qassim). 2019;13(4):48\u201355.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"4","key":"2639_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40620-013-0036-x","volume":"27","author":"JP Baptista","year":"2014","unstructured":"Baptista JP, Neves M, Rodrigues L, Teixeira L, Pinho J, Pimentel J. Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients. J Nephrol. 2014;27(4):403\u201310.","journal-title":"J Nephrol"},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13054-019-2515-5","volume":"23","author":"PM Honore","year":"2019","unstructured":"Honore PM, De Bels D, Attou R, Redant S, Gallerani A, Kashani K. Attainment of therapeutic vancomycin level within the first 24 h. Crit Care. 2019;23:228.","journal-title":"Crit Care"},{"issue":"6","key":"2639_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s13054-014-0654-2","volume":"18","author":"JP Baptista","year":"2014","unstructured":"Baptista JP, Roberts JA, Sousa E, Freitas R, Deveza N, Pimentel J. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. Crit Care. 2014;18(6):654.","journal-title":"Crit Care"},{"issue":"7","key":"2639_CR5","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","volume":"42","author":"JA Jamal","year":"2014","unstructured":"Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med. 2014;42(7):1640\u201350.","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-019-2639-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-019-2639-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-019-2639-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:11:45Z","timestamp":1605139905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-019-2639-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1186\/s13054-019-2639-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"type":"electronic","value":"1364-8535"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"29 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAR: Consultancies\/Advisory Boards \u2013 MSD (2019); QPEX (2019); Discuva Ltd. (2019); Accelerate Diagnostics (2017); Bayer (2017); Biomerieux (2016). Speaking Fees \u2013 MSD (2018); Biomerieux (2018). Industry Grants \u2013 MSD (2017); The Medicines Company (2017); Cardeas Pharma (2016); Biomerieux (2019).All the other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}